Announcements Trials
Browse Landscape

Phase

Phase 2 63Phase 1 35Phase 3 16Phase 1/2 16Phase NA 10Phase 2/3 2Phase EARLY_PHASE1 1

Status

Not yet recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Neoplasms 37Carcinoma, Non-Small-Cell Lung 29Prostatic Neoplasms 20Neoplasm Metastasis 19Breast Neoplasms 19Colorectal Neoplasms 17Squamous Cell Carcinoma of Head and Neck 14Leukemia, Myeloid, Acute 14Stomach Neoplasms 12Ovarian Neoplasms 12Melanoma 12Lung Neoplasms 12Carcinoma, Hepatocellular 12Recurrence 11Hematologic Neoplasms 10Endometrial Neoplasms 10Rectal Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Pancreatic Neoplasms 9Lymphoma 9Head and Neck Neoplasms 9Myasthenia Gravis 8Leukemia 8Urinary Bladder Neoplasms 7Neoplasms by Site 7Neoplasms by Histologic Type 7Lymphoma, Large B-Cell, Diffuse 7Glioblastoma 7Fatigue 6Colonic Neoplasms 6

Interventions

Fluorouracil 2tislelizumab 1Paclitaxel 1Cisplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Esophageal Squamous Cell Carcinoma × 1 year × Clear all
NCT07554456 2026-04-28

A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)

Sichuan Baili Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
90 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT07251062 2025-11-26

A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.

CSPC Megalith Biopharmaceutical Co.,Ltd.

Phase 2/3 Not yet recruiting
737 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡